Immunotherapy in Renal Cell Carcinoma: The Future Is Now

被引：181

作者：

Deleuze, Antoine ^{[1
,2
]}

Saout, Judikael ^{[1
]}

Dugay, Frederic ^{[1
,3
]}

Peyronnet, Benoit ^{[4
]}

Mathieu, Romain ^{[1
,4
]}

Verhoest, Gregory ^{[4
]}

Bensalah, Karim ^{[4
]}

Crouzet, Laurence ^{[2
]}

Laguerre, Brigitte ^{[2
]}

Belaud-Rotureau, Marc-Antoine ^{[1
,3
]}

Rioux-Leclercq, Nathalie ^{[1
,5
]}

Kammerer-Jacquet, Solene-Florence ^{[1
,5
]}

机构：

[1] Univ Rennes, EHESP Ecole Hautes Etud Sante Publ, IRSET Inst Rech Sante Environm & Travail, Inserm,UMR 1085, F-35000 Rennes, France

[2] Ctr Eugene Marquis, Dept Med Oncol, F-35000 Rennes, France

[3] Univ Hosp, Dept Cytogenet, F-35000 Rennes, France

[4] Univ Hosp, Dept Urol, F-35000 Rennes, France

[5] Univ Hosp, Dept Pathol, F-35000 Rennes, France

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 07期

关键词：

immunotherapy; immune checkpoint inhibitors; renal cell carcinoma; PD-1; PD-L1; ongoing trials; biomarkers; emerging drugs; TUMOR-CELLS; PD-L1; EXPRESSION; INTERFERON-ALPHA; SUNITINIB; NIVOLUMAB; EVEROLIMUS; RESISTANCE; INHIBITION; RECEPTORS; THERAPIES;

D O I：

10.3390/ijms21072532

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Renal cell carcinoma is the third type of urologic cancer and has a poor prognosis with 30% of metastatic patients at diagnosis. The antiangiogenics and targeted immunotherapies led to treatment remodeling emphasizing the role of the tumour microenvironment. However, long-term responses are rare with a high rate of resistance. New strategies are emerging to improve the efficacy and the emerging drugs are under evaluation in ongoing trials. With the different treatment options, there is an urgent need to identify biomarkers in order to predict the efficacy of drugs and to better stratify patients. Owing to the limitations of programmed death-ligand 1 (PD-L1), the most studied immunohistochemistry biomarkers, and of the tumor mutational burden, the identification of more reliable markers is an unmet need. New technologies could help in this purpose.

引用

页数：22

共 97 条

[1] Axitinib for the treatment of advanced renal cell carcinoma [J].

Akaza, Hideyuki ;

Fukuyama, Tomofusa .

EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (02) :283-297

[2] Cytogenetic Abnormalities of Tumor-Associated Endothelial Cells in Human Malignant Tumors [J].

Akino, Tomoshige ;

Hida, Kyoko ;

Hida, Yasuhiro ;

Tsuchiya, Kunihiko ;

Freedman, Deborah ;

Muraki, Chikara ;

Ohga, Noritaka ;

Matsuda, Kouhei ;

Akiyama, Kousuke ;

Harabayashi, Toru ;

Shinohara, Nobuo ;

Nonomura, Katsuya ;

Klagsbrun, Michael ;

Shindoh, Masanobu .

AMERICAN JOURNAL OF PATHOLOGY, 2009, 175 (06) :2657-2667

[3] Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma [J].

Albiges, Laurence ;

Powles, Tom ;

Staehlerr, Michael ;

Bensalan, Karim ;

Giles, Rachel H. ;

Hora, Milan ;

Kuczyk, Markus A. ;

Lam, Thomas B. ;

Ljungberg, Brje ;

Marconi, Lorenzo ;

Merseburger, Axel S. ;

Volpe, Alessandro ;

Abu-Ghanem, Yasmin ;

Dabestani, Saeed ;

Fernandez-Pello, Sergio ;

Hofmann, Fabian ;

Kuusk, Teele ;

Tahbaz, Rana ;

Bex, Axel .

EUROPEAN UROLOGY, 2019, 76 (02) :151-156

[4]

Ananieva Elitsa, 2015, World J Biol Chem, V6, P281, DOI 10.4331/wjbc.v6.i4.281

[5] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].

Anderson, Ana C. ;

Joller, Nicole ;

Kuchroo, Vijay K. .

IMMUNITY, 2016, 44 (05) :989-1004

[6] MiT family translocation renal cell carcinoma [J].

Argani, Pedram .

SEMINARS IN DIAGNOSTIC PATHOLOGY, 2015, 32 (02) :103-113

[7] Rationale for anti-OX40 cancer immunotherapy [J].

Aspeslagh, Sandrine ;

Postel-Vinay, Sophie ;

Rusakiewicz, Sylvie ;

Soria, Jean-Charles ;

Zitvogel, Laurence ;

Marabelle, Aurelien .

EUROPEAN JOURNAL OF CANCER, 2016, 52 :50-66

[8] Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression [J].

Becht, Etienne ;

Giraldo, Nicolas A. ;

Lacroix, Laetitia ;

Buttard, Benedicte ;

Elarouci, Nabila ;

Petitprez, Florent ;

Selves, Janick ;

Laurent-Puig, Pierre ;

Sautes-Fridman, Catherine ;

Fridman, Wolf H. ;

de Reynies, Aurelien .

GENOME BIOLOGY, 2016, 17

[9] Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade [J].

Benci, Joseph L. ;

Xu, Bihui ;

Qiu, Yu ;

Wu, Tony J. ;

Dada, Hannah ;

Twyman-Saint Victor, Christina ;

Cucolo, Lisa ;

Lee, David S. M. ;

Pauken, Kristen E. ;

Huang, Alexander C. ;

Gangadhar, Tara C. ;

Amaravadi, Ravi K. ;

Schuchter, Lynn M. ;

Feldman, Michael D. ;

Ishwaran, Hemant ;

Vonderheide, Robert H. ;

Maity, Amit ;

Wherry, E. John ;

Minn, Andy J. .

CELL, 2016, 167 (06) :1540-+

[10] 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer [J].

Bensch, Frederike ;

van der Veen, Elly L. ;

Lub-de Hooge, Marjolijn N. ;

Jorritsma-Smit, Annelies ;

Boellaard, Ronald ;

Kok, Iris C. ;

Oosting, Sjoukje F. ;

Schroder, Carolina P. ;

Hiltermann, T. Jeroen N. ;

van der Wekken, Anthonie J. ;

Groen, Harry J. M. ;

Kwee, Thomas C. ;

Elias, Sjoerd G. ;

Gietema, Jourik A. ;

Bohorquez, Sandra Sanabria ;

de Crespigny, Alex ;

Williams, Simon-Peter ;

Mancao, Christoph ;

Brouwers, Adrienne H. ;

Fine, Bernard M. ;

de Vries, Elisabeth G. E. .

NATURE MEDICINE, 2018, 24 (12) :1852-+

← 1 2 3 4 5 6 7 8 9 10 →